Alzheimer’s Disease Market Growth Driven by Innovative Developments Such as INmune Bio Inc.’s (NASDAQ: INMB) XPro1595
Companies like INmune Bio are advancing the development of innovative treatment methods INmune’s lead drug candidate, XPro1595, works by targeting neuroinflammation, one of the causes of Alzheimer’s XPro1595 is set to undergo a phase I clinical trial in the summer of 2019 with a goal of measuring traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer’s The global market for Alzheimer’s disease (AD) treatments is forecast to double in value by 2023, reaching $4.9 billion, according to GlobalData research (http://ibn.fm/8ZqMy). The growth rate has been estimated at 10.5 percent for the forecast period. The increasing prevalence of…